Cinfa Biotech’s team consists of 20 renowned biosimilar experts who have a proven track record in developing and launching biosimilars and biopharmaceuticals in different indications. With a deep understanding of protein-based therapeutics and disease biology, we are able to define efficient biosimilar development programs, based on the most actual scientific, regulatory considerations for the establishment and confirmation of biosimilarity. Our team enjoys the great support of the entire Infarco group as well as the freedom to pioneer the biosimilar business.